Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6143515 | 1.00 | PAOX (0.46) | PAOXALOX15MC4RKDM1ASIGMAR1 | |
| SCHEMBL21594786 | 0.96 | PAOX (0.44) | PAOXALOX15MC4RKDM1ASIGMAR1 | |
| SCHEMBL2616296 | 0.90 | PRMT6 (0.48) | PAOXKDM1ASIGMAR1 | |
| SCHEMBL11955737 | 0.90 | CHKA (0.48) | PAOXSIGMAR1 | |
| SCHEMBL19826457 | 0.87 | HRH3 (0.52) | PAOXCYP1A2 | |
| SCHEMBL2056177 | 0.87 | HRH3 (0.52) | PAOXCYP1A2 | |
| SCHEMBL21908086 | 0.87 | PAOX (0.40) | PAOXALOX15MC4RKDM1ASIGMAR1 | |
| SCHEMBL2376506 | 0.87 | DRD2 (0.45) | PAOXALOX15MC4RKDM1ASIGMAR1 | |
| SCHEMBL22957950 | 0.87 | KDM1A (0.41) | PAOXALOX15MC4RKDM1ASIGMAR1 | |
| SCHEMBL27250180 | 0.87 | CHKA (0.52) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 401 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577505-B2 | Granules comprising protonated triazacyclic compounds and bleaching agent and cleaning agent comprising the same | CATEXEL GMBH (DE) | 2026-03-17 | — | — | US | claimed |
| US-12568971-B2 | Degradative method | CATEXEL TECHNOLOGIES LIMITED (GB) | 2026-03-10 | — | — | US | claimed |
| EP-4256018-B1 | GRANULES COMPRISING PROTONATED TRIAZACYCLIC COMPOUNDS AND BLEACHING AGENT AND CLEANING AGENT COMPRISING THE SAME | WeylChem Performance Products GmbH (DE) | 2025-07-16 | — | — | EP | claimed |
| CN-119490893-A | Liquid formulations comprising alcohol and high water-soluble manganese complex salt catalysts, bleaching formulations and cleaners comprising the same | 卡特赛尔有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-115175944-B | Degradation method | 卡特克塞尔科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-4110831-B1 | DEGRADATIVE METHOD | CATEXEL TECH LIMITED (GB) | 2024-02-21 | — | — | EP | claimed |
| US-20240034962-A1 | GRANULES COMPRISING PROTONATED TRIAZACYCLIC COMPOUNDS AND BLEACHING AGENT AND CLEANING AGENT COMPRISING THE SAME | CATEXEL GMBH (DE) | 2024-02-01 | — | — | US | claimed |
| US-20230416658-A1 | COMPOSITIONS COMPRISING PROTONATED TRIAZACYCLIC COMPOUNDS AND MANGANESE(II) ACETATE, MANUFACTURING THEREOF, AND BLEACHING AND CLEANING AGENT COMPRISING SAME | CATEXEL GMBH (DE) | 2023-12-28 | — | — | US | claimed |
| EP-4296343-A1 | COMPOSITIONS COMPRISING PROTONATED TRIAZACYCLIC COMPOUNDS AND MANGANESE(II) ACETATE, MANUFACTURING THEREOF, AND BLEACHING AND CLEANING AGENT COMPRISING SAME | WeylChem Performance Products GmbH (DE) | 2023-12-27 | — | — | EP | claimed |
| EP-4296344-A1 | COMPOSITIONS COMPRISING PROTONATED TRIAZACYCLIC COMPOUNDS AND MANGANESE(II) ACETATE, MANUFACTURING THEREOF, AND BLEACHING AND CLEANING AGENT COMPRISING SAME | WeylChem Performance Products GmbH (DE) | 2023-12-27 | — | — | EP | claimed |
| WO-2008098921-A1 | STORAGE-STABLE SURFACTANT SOLUTIONS FOR PEROXIDE BLEACHES | CHT R. BEITLICH GMBH (DE) | 2008-08-21 | — | — | WO | claimed |
| WO-2008086937-A2 | BLEACHING OF SUBSTRATES | UNILEVER PLC (GB) | 2008-07-24 | — | — | WO | claimed |
| EP-1934396-A2 | BLEACHING OF SUBSTRATES | Unilever PLC (GB) | 2008-06-25 | — | — | EP | claimed |
| EP-1883730-A1 | PROCESS OF BLEACHING | Unilever Plc (GB) | 2008-02-06 | — | — | EP | claimed |
| WO-2007042192-A2 | BLEACHING OF SUBSTRATES | UNILEVER PLC (GB) | 2007-04-19 | — | — | WO | claimed |
| WO-2006125517-A1 | PROCESS OF BLEACHING | UNILEVER PLC (GB) | 2006-11-30 | — | — | WO | claimed |
| US-5667690-A | Process for removing noxious compounds | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST - NATUURWETENSCHAPPELIJK (NL) | 1997-09-16 | — | — | US | claimed |
| EP-0672104-B1 | PROTECTION OF ADJUNCTS | UNILEVER PLC (GB) | 1997-07-02 | — | — | EP | claimed |
| US-5601750-A | CONTAINING ENZYMATIC HYDROGEN PEROXIDE GENERATING SYSTEM, IRON OR MANGANESE COORDINATION COMPLEX BLEACH CATALYST, ENZYMATIC ALDEHYDE DECOMPOSING SYSTEM COMPRISING INTACT YEAST CELLS | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1997-02-11 | — | — | US | claimed |
| WO-1995030733-A1 | BLEACH CATALYST COMPOSITION | UNILEVER N.V. (NL) | 1995-11-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12568971-B2 | Degradative method | MACO1, MPO, ITGB1 | PAOX 450/4885ALOX15 456/4885MC4R 2518/4885 |
| US-12577505-B2 | Granules comprising protonated triazacyclic compounds and bleaching agent and cleaning agent comprising the same | HBG2, HBG1, BLM | PAOX 606/4885ALOX15 1457/4885MC4R 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.